Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Return on Equity (2016 - 2025)

Historic Return on Equity for Ligand Pharmaceuticals (LGNYZ) over the last 13 years, with Q3 2025 value amounting to 0.05%.

  • Ligand Pharmaceuticals' Return on Equity changed N/A to 0.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.05%, marking a year-over-year change of. This contributed to the annual value of 0.01% for FY2024, which is 0.0% changed from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Return on Equity stood at 0.05% for Q3 2025.
  • Ligand Pharmaceuticals' Return on Equity's 5-year high stood at 0.05% during Q3 2025, with a 5-year trough of 0.09% in Q1 2025.
  • In the last 5 years, Ligand Pharmaceuticals' Return on Equity had a median value of 0.02% in 2021 and averaged 0.02%.
  • In the last 5 years, Ligand Pharmaceuticals' Return on Equity surged by 1200bps in 2021 and then plummeted by -600bps in 2022.
  • Ligand Pharmaceuticals' Return on Equity (Quarter) stood at 0.02% in 2021, then plummeted by -69bps to 0.04% in 2022, then soared by 94bps to 0.0% in 2023, then plummeted by -1429bps to 0.04% in 2024, then soared by 247bps to 0.05% in 2025.
  • Its Return on Equity stands at 0.05% for Q3 2025, versus 0.08% for Q2 2025 and 0.09% for Q1 2025.